Q-omics provides the consensus-scored ANKRD11P2 profile across patient tissues and cancer cell-line models. ANKRD11P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ANKRD11P2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ANKRD11P2 RNA expression shows 15,428 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, HNSC, and THYM as cancer lineages where ANKRD11P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD11P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD11P2 survival associations across molecular data types. ANKRD11P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD11P2 RNA expression–survival associations across cancer types. High ANKRD11P2 expression shows unfavorable associations in KICH, LIHC, LUAD and COAD, but favorable associations in SKCM and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for ANKRD11P2 RNA expression.
This table summarizes ANKRD11P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD11P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD11P2 shows higher tumor expression in HNSC, COAD, STAD, CHOL, KIRC and LIHC. The HNSC box plot shows higher ANKRD11P2 RNA expression in tumor versus normal tissue (log2 FC = +0.151, t-test p = .006).
This table shows molecular features associated with ANKRD11P2 in patient tissues and cancer cell lines. In patient samples, ANKRD11P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
